New research indicates that individuals who come off popular GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who stop traditional diet and exercise plans.
Published data in a major medical journal demonstrates that while obese people often shed about a fifth of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these treatments need to be aware of the danger of quick rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original weight within about one and a half years.
Weighing Approaches
The analysis, which looked at dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
Researchers note that people who lose weight through dieting typically experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Rapid Regain
Nutrition scientists suggest the mechanism of the jabs accounts for the heightened weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making excessive eating much more probable."
An Ongoing Condition?
The NHS recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the significant potential of relapse, the therapy is often long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure.
User Testimonies
Users who have come off the medication describe a sudden return of appetite.
"It felt as if a trigger activating and you become ravenous," described a patient.
This difficulty is worsened if patients have not developed lasting dietary or behavioural modifications during therapy.
Significant Use
Figures show that a significant number of adults in the UK have used these injections in the past year, with demand remaining high.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while these medications are effective agents for weight loss, they are not a standalone solution and long-term success relies on integrated behavioural management.
